Use of anti-diabetic drugs and glycaemic control in type 2 diabetes-The Hong Kong Diabetes Registry
Publication in refereed journal

Times Cited
Web of Science37WOS source URL (as at 15/10/2020) Click here for the latest count
Altmetrics Information

Other information
AbstractIn this report, we examined the usage of anti-diabetic treatments including oral antidiabetic drug (OAD) and/or insulin and their combination from baseline data of a consecutive cohort of 7549 Chinese type 2 diabetic subjects in the Hong Kong Diabetes Registry. Pattern of usage of anti-diabetic treatment and corresponding glycemic control was analyzed. OAD failure was defined as the need to add insulin to maintain glycemic target (glycated hemoglobin, HbA(1c) level < 7%) with or without continuation of OAD. There were 4109 [54.4%] women and 3440 [45.6%] men (age: median 57.0 years; range 13-92 years). The mean HbA(1c) level was 7.7 +/- 1.8% with 39.7% attaining glycemic target. Long disease duration was associated with more complex regimens and the respective rates of OAD failure requiring insulin use were 23.7%, 39.3%, 57.1% and 75.9% in those with disease duration < 5 years, 5-9.9 years, 10-19.9 years and >= 20 years (p < 0.001). In conclusion, in a clinic-based type 2 diabetic population, 39.7% attained glycemic target with HbA(1c) < 7%. Long disease duration and complexity of treatment regimens were associated with suboptimal glycemic control. Early intensification of therapy and system improvement are needed to enhance the effectiveness of these drugs in clinical practice. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
All Author(s) ListTong PCY, Ko GTC, So WY, Chiang SC, Yang XL, Kong APS, Ozaki R, Ma RCW, Cockram CS, Chow CC, Chan JCN
Journal nameDiabetes Research and Clinical Practice
Volume Number82
Issue Number3
Pages346 - 352
LanguagesEnglish-United Kingdom
KeywordsChinese; Drug treatment; Glycaemic control; Type 2 diabetes
Web of Science Subject CategoriesEndocrinology & Metabolism; ENDOCRINOLOGY & METABOLISM

Last updated on 2020-16-10 at 00:30